Biotechnology - Neurological, Bayer

Filter

Current filters:

NeurologicalBayer

Popular Filters

Genzyme to resubmit Lemtrada NDA for FDA review

Genzyme to resubmit Lemtrada NDA for FDA review

07-04-2014

Genzyme, the biotech subsidiary of French drug major Sanofi, said this morning that, following “constructive…

BayerBiotechnologyLemtradaNeurologicalNorth AmericaRegulationSanofiUSA

Pfenex and Agila Biotech set up JV to develop biosimilars

16-04-2013

US biotech firm Pfenex Inc. and Agila Biotech, a subsidiary of Indian drugmaker Strides Arcolab (BO:…

Agila BiotechBayerBetaferonBetaseronBiotechnologyGenericsGlobalNeurologicalPfenexProductionResearchStrides Arcolab

FDA calls on Genzyme to re-file Lemtrada sBLA

28-08-2012

French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada

26-06-2012

More than 85% of surveyed neurologists in the European Union-5 (France, Germany, Italy, Spain and the…

AubagioBayerBG-12Biogen IdecBiotechnologyEuropeLemtradaMarkets & MarketingNeurologicalPharmaceuticalSanofi

Genzyme files multiple sclerosis drug Lemtrada with FDA and EMA

12-06-2012

French drug major Sanofi (Euronext: SAN) subsidiary Genzyme revealed this morning that it has submitted…

BayerBiotechnologyEuropeGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Back to top